NTLA

Intellia Therapeutics Inc

NTLA, USA

Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

https://www.intelliatx.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
NTLA
stock
NTLA

623,600 Shares in Intellia Therapeutics, Inc. $NTLA Acquired by Marex Group plc MarketBeat

Read more →
NTLA
stock
NTLA

Intellia Therapeutics, Inc. $NTLA Shares Sold by Nikko Asset Management Americas Inc. MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$22.4318

Analyst Picks

Strong Buy

18

Buy

4

Hold

6

Sell

1

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

1.33

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-13.54 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-10.95 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-558.18 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.24

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 108.93% of the total shares of Intellia Therapeutics Inc

1.

ARK Investment Management LLC

(12.1269%)

since

2025/06/30

2.

Vanguard Group Inc

(10.1094%)

since

2025/06/30

3.

BlackRock Inc

(9.3409%)

since

2025/06/30

4.

ARK Disruptive Innovation Full Composite

(8.1093%)

since

2025/06/30

5.

ARK Innovation ETF

(7.7088%)

since

2025/08/28

6.

Morgan Stanley - Brokerage Accounts

(3.8351%)

since

2025/06/30

7.

State Street Corp

(3.7628%)

since

2025/06/30

8.

Regeneron Pharmaceuticals Inc

(3.4496%)

since

2025/06/30

9.

Vanguard Total Stock Mkt Idx Inv

(2.9488%)

since

2025/07/31

10.

ARK Genomic Revolution ETF

(2.694%)

since

2025/08/28

11.

ARK Genomic Revolution

(2.6811%)

since

2025/06/30

12.

Baker Bros Advisors LP

(2.4925%)

since

2025/06/30

13.

Amova Asset Management Americas, Inc

(2.4884%)

since

2025/06/30

14.

Sumitomo Mitsui Trust Group Inc

(2.4884%)

since

2025/06/30

15.

Geode Capital Management, LLC

(2.4279%)

since

2025/06/30

16.

Vanguard Small Cap Index

(2.3412%)

since

2025/07/31

17.

iShares Russell 2000 ETF

(2.3147%)

since

2025/08/31

18.

Two Sigma Investments LLC

(2.1208%)

since

2025/06/30

19.

Two Sigma Advisers, LLC

(1.9498%)

since

2025/06/30

20.

Goldman Sachs Group Inc

(1.9071%)

since

2025/06/30

21.

Dimensional Fund Advisors, Inc.

(1.7386%)

since

2025/06/30

22.

Amova ARK Disruptive Innovation A USD

(1.5811%)

since

2025/07/31

23.

SPDR® S&P Biotech ETF

(1.4617%)

since

2025/08/31

24.

VOLORIDGE INVESTMENT MANAGEMENT, LLC

(1.4469%)

since

2025/06/30

25.

Contrarius Group Holdings Ltd

(1.4463%)

since

2025/06/30

26.

FMR Inc

(1.4165%)

since

2025/06/30

27.

Contrarius Global Equity Institutional

(1.3474%)

since

2025/06/30

28.

Vanguard Small Cap Growth Index Inv

(1.3118%)

since

2025/07/31

29.

Balyasny Asset Management LLC

(1.2217%)

since

2025/06/30

30.

Woodline Partners LP

(1.1356%)

since

2025/06/30

31.

Trexquant Investment LP

(1.0502%)

since

2025/06/30

32.

Vanguard Institutional Extnd Mkt Idx Tr

(1.0341%)

since

2025/07/31

33.

Fidelity Small Cap Index

(0.9652%)

since

2025/06/30

34.

Fidelity Select Biotechnology

(0.9131%)

since

2025/07/31

35.

iShares Russell 2000 Value ETF

(0.8514%)

since

2025/08/31

36.

Amova ARK Pstv Chg Innovt P JPY Acc

(0.6001%)

since

2025/07/31

37.

Vanguard Strategic Equity Inv

(0.5875%)

since

2025/06/30

38.

iShares Biotechnology ETF

(0.5405%)

since

2025/08/31

39.

Fidelity Extended Market Index

(0.5233%)

since

2025/07/31

40.

BlackRock Advantage Small Cap Core Instl

(0.4634%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.92

EPS Estimate

-1.01

EPS Difference

0.09

Surprise Percent

8.9109%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(1)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(3)
Value
Fair Value(5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.